CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate

Justin J. Leitenberger, Cindy N. Berthelot*, Kristel D. Polder, Barbara Pro, Peter McLaughlin, Dan Jones, Madeleine Duvic

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

The CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor is a rare, highly aggressive, systemic neoplasm for which effective therapies have not yet been established. These tumors express CD4, CD56, CD123, and T-cell leukemia/lymphoma (TCL)-1 and are clinically characterized by cutaneous involvement with spread to bone marrow and blood, and poor prognosis with current chemotherapy regimens. We describe a Caucasian woman who presented with plasmacytoid dendritic cell tumor, but an absence of systemic symptoms. Clinically, multiple cutaneous lesions were brown to violaceous firm nodules on the face, arms, and trunk. The patient underwent two courses of cyclophosphamide, Adriamycin, vincristine, and prednisone chemotherapy but relapsed quickly. The investigational agent, pralatrexate (30 mg/m2) was given weekly with vitamin B12 and folic acid and resulted in remarkable clinical response with regression of skin tumors. Our observation highlights pralatrexate as a promising therapeutic option for hematodermic/plasmacytoid dendritic cell lymphoma/leukemias.

Original languageEnglish (US)
Pages (from-to)480-484
Number of pages5
JournalJournal of the American Academy of Dermatology
Volume58
Issue number3
DOIs
StatePublished - Mar 2008

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'CD4<sup>+</sup> CD56<sup>+</sup> hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate'. Together they form a unique fingerprint.

Cite this